Introduction
A number of pulmonary conditions may accompany portal hypertension. Most cases of portal hypertension in western countries are associated with cirrhosis. This situation is not always true, especially in developing countries where noncirrhotic portal hypertension may be associated with pulmonary complications.
The two syndromes, portopulmonary hypertension (POPH) and hepatopulmonary syndrome (HPS) are apparently opposite responses to a single clinical condition. The reason for this paradox is unknown. Neither condition is associated with a particular cause of portal hypertension, and neither is related to the degree of portal hypertension. Rare patients with features of both conditions have been described. This review describes the important features of both conditions with emphasis on recent findings.
Portopulmonary hypertension
Definition POPH is a condition of increased resistance to pulmonary blood flow in the setting of portal hypertension [1] . POPH has been defined as mean pulmonary artery pressure (MPAP) more than 25 mmHg at right heart catheterization, and is commonly seen in cirrhotic patients. Moderate and severe POPH (MPAP !35 and !45 mmHg, respectively) are less common, and more serious. Historic data show that mortality after orthotopic liver transplantation (OLT) is 50% for MPAP more than 35 mmHg, and 100% for MPAP more than 45 mmHg [2, 3] .
We now recognize several factors that increase pulmonary pressure including pulmonary vascular resistance (PVR), high cardiac output and elevated left atrial pressure. The relationship between these factors is explained in the formula for PVR, and has led to a revision of the definition for POPH. We now include PVR and exclude left ventricular failure in the definition as proposed by the European Respiratory Society and the European Society for the Study of the Liver (ERS-EASL) Task Force on Hepatic-Pulmonary Vascular Disorders of POPH [4] follows:
(1) Portal hypertension and/or liver disease by clinical findings. (2) Mean pulmonary artery pressure (MPAP) at least 25 mmHg. (3) PVR at least 240 dynes.s.cm À5 .
Purpose of review
To summarize the pulmonary complications seen in cirrhosis.
Recent findings
The definition of portopulmonary hypertension (POPH) has been refined to exclude cardiac disease. POPH may be treated with a variety of agents; inhaled agents are particularly useful in the peri-transplant period. Hepatopulmonary syndrome (HPS) remains refractory to medical therapy. Summary Cirrhosis may be complicated by one of two pulmonary vascular complications, portopulmonary hypertension (POPH) and hepatopulmonary syndrome (HPS). POPH is a syndrome of increased vascular resistance, initiated by pulmonary vascular spasm. HPS is caused by intrapulmonary arteriovenous shunting with resultant hypoxemia. Both conditions are associated with portal hypertension, but are unrelated to the degree of portal hypertension, the nature or severity of the liver disease, and are associated with mortality in excess of the model for end-stage liver disease score. POPH is usually responsive to vasodilators, while HPS remains resistant to therapeutic agents. Both conditions are improved or cured by liver transplantation.
(4) Pulmonary artery occlusion pressure (PAOP) 12 mmHg or less.
MPAP and PAOP are measured directly, whereas PVR is calculated by the formula
where PVR is pulmonary vascular resistance in dynes.s.cm À5 ; MPAP is mean pulmonary artery pressure PAOP is pulmonary occlusion (wedge) pressure; CO is the cardiac output.
Looking at the formula for PVR, we can see that a number of factors apart from vascular spasm might cause or contribute to pulmonary artery hypertension. These are explained in Fig. 1 .
Diagnosis
POPH is frequently asymptomatic and is usually first suspected on a screening echocardiogram that shows an elevated right ventricular systolic pressure (RVSP). Liver transplant centers routinely screen transplant candidates for both POPH and HPS with contrast-enhanced echocardiography; elevated RVSP on echocardiogram should be followed with right heart catheterization (RHC). Using echocardiography, RVSP is estimated on tricuspid regurgitant velocity using a modified Bernoulli equation
where RSVP is right ventricular systolic pressure in mmHg and TR is right tricuspid regurgitant peak velocity in m/s. Most centers consider RHC if the RSVP is more than 50 mmHg [5] .
The correlation between echocardiography and RHC was addressed in a study by Krowka et al. [1] . One hundred and four of 1235 patients had RSVP more than 50 mmHg, and 101 of these underwent RHC. Thirty-five percent of the group had PVR less than 240 mmHg, and almost half the cases had elevated pulmonary artery opening pressure (i.e. were volume overloaded). Of the 68 patients with PVR more than 240 dynes.s.cm À5 , only 41 had significant POPH (PVR >400 dynes.s.cm À5 ). The authors concluded that RSVP at least 50 mmHg was a reasonable threshold for RHC, that RHC was essential to determining the cause of high RSVP, and that model for end-stage liver disease (MELD) score did not correlate with hemodynamic measurements.
Pathogenesis
The pathology and physiological consequences of POPH are well described, but we have been able to identify neither the basis for these changes nor explain why only 6-8% of cirrhotic patients develop the condition. A multicenter group has been very active in this field, and has published three important papers:
(1) A case-control study identified 34 patients and found that POPH was more common in women and patients with autoimmune disease [6] . The utility to these findings is difficult to assess because most centers have seen patients of both sexes with a variety of etiologies. On the contrary, the single nucleotide polymorphism (SNP) analysis below lends credence to their findings. (2) A mutation in the serotonin transporter is associated with an increased risk of some forms of pulmonary arterial hypertension, but was not associated with POPH [7] . (3) SNP analysis on 31 patients and 101 controls found 29 SNPs in 15 candidate genes that were associated with the risk of POPH (P < 0.05). The genes included estrogen receptor-1, aromatase, phosphodiesterase-5 (PDE-5), angiopoietin-1, and calcium binding protein A-4 [8] . Although the statistical significance 282 Liver transplantation
Key points
Constriction and dilitation of the pulmonary vascular bed improve after liver transplantation. Liver disease and portal hypertension may be associated with these conditions. is low for this type of analysis, the biological relevance of the aromatase SNPs was supported by an association with plasma estradiol levels.
A recent paper compared a number of cytokines in patients with POPH, hyperdynamic circulation or uncomplicated cirrhosis. The cytokines studied included endothelin-1, interleukin-6, interleukin-1-beta, and TNF-a. Patients with POPH had significantly higher levels of endothelin-1 and interleukin-6, suggesting that inhibitors of these two cytokines might be beneficial in treating POPH [9] .
Clinical features
Clinical findings in POPH are subtle or nonexistent. Exertional dyspnea is rarely a presenting feature. A loud pulmonic component to the second heart sound is reported in about 30% of patients, but is unreliable; screening echocardiography remains the mainstay of diagnosis.
Natural history
The natural history of POPH has been difficult to study. An early report of POPH found mean survival of 15 months [10] . The most reliable data come from a retrospective study of 74 patients seen at Mayo Clinic between 1994 and 2007 [11] . Patients were divided into three groups:
( (a) 5-year survival for patients who were treated prior to OLT ¼ 67% and (b) 5-year survival for patients who were not treated prior to OLT ¼ 25%.
The authors concluded that any therapy was better than no therapy, and that the severity of POPH was unrelated to the severity or cause of liver disease. Their observations also suggested that vasodilator therapy might make OLT possible.
Management
Management of POPH is an exciting field with a growing number of treatment options including vasodilators and liver transplantation.
Vasodilators
Vasodilators are appropriate and effective in pulmonary hypertension, but they should not be used unless a high EPO may also be delivered by aerosol, and may be useful in the perioperative management of portal hypertension [12] . Its use in POPH is not reported although we and others have used it successfully during and after OLT (M. Krowka, M. Ramsay, personal communication, February 2011).
Two other prostanoids available are treprostinil (remodulin), and iloprost (ventavis). Treprostinil may be given subcutaneously or intravenously. Subcutaneous dosing may be limited by pain, and the intravenous administration is not as effective as EPO. Iloprost is an inhaled drug that has an immediate effect on MPAP. Its longterm use is hampered by it short half-life, requiring dosing six to nine times daily. In a recent study of 12 patients followed for at least 12 months, functional class and 6-min walk distance improved, but systolic pulmonary artery pressure (by echocardiogram) did not change, two patients died, and four suffered hepatic or pulmonary decompensation [13] .
Endothelin receptor antagonists
Endothelin receptors are G protein-coupled receptors; activation leads to elevated intracellular calcium levels. Three receptors have been described, endothelin (ET) A , ET B1 and ET B2 . Therapeutic agents include the nonspecific antagonist, bosentan (Tracleer), and the ET A -specific agents, ambrisentan (Letairis), sitaxsentan (Thelin) and atrasentan.
Bosentan use in POPH has been limited in part because of fears of idiosyncratic hepatotoxicity. Bosentan as a single agent [14] or in combination with other vasodilators [15] has been described, but experience in POPH is limited. Ambrisentan monotherapy proved nonhepatotoxic in 13 patients with POPH treated for a median of 390 days [16] . MPAP and PVR improved, two patients died, and one was transplanted successfully.
Phosphodiesterase-5 inhibitors
PDE-5 inhibitors prevent the breakdown of cyclic guanosine monophosphate (cGMP), the mediator of nitric oxide-induced vasodilation [17] and, thus, reduce pulmonary artery pressure [18] . The most recognizable agent is sildenafil, which has proven effective and well tolerated in several small series of POPH [19] [20] [21] . Other drugs in this class include vardenafil and tadalafil [18, 22] .
Nitric oxide
Inhaled nitric oxide is a potent vasodilator, and very effective for acutely managing pulmonary hypertension. It is very expensive, and is generally used while the patient is intubated. Its use in POPH has not been reported, but anecdotal reports suggest it is highly effective for controlling pulmonary artery pressure during surgery.
Liver transplantation
Although POPH may occur in the setting of noncirrhotic portal hypertension, the majority of patients in western countries have cirrhosis. The role of liver transplantation in the management of POPH has changed several times. When the danger of perioperative death was established, many centers simply turned down patients with POPH. With the availability of potent vasodilators, several centers reported successful OLT once POPH was controlled [23] [24] [25] . This observation has been extended to livingrelated donors [26] .
We now recognize that patients can be transplanted safely if MPAP is controlled and the patient does not have right heart failure. The anesthesiologist must be prepared, and pharmacologic agents (inhaled EPO or nitric oxide) must be available in the event of a hypertensive crisis). The pulmonary artery pressure usually improves after OLT although patients may require ongoing therapy with an oral agent.
Hepatopulmonary syndrome
Definition HPS is commonly defined as a widened age-corrected alveolar-arterial oxygen gradient on room air, with or without hypoxemia, occurring as a result of intrapulmon-ary microvascular vasodilatation in the presence of cirrhosis and/or portal hypertension [27] . Older definitions of HPS required exclusion of intrinsic cardiopulmonary disease in order to establish the diagnosis although recent studies indicate that HPS may coexist with other cardiopulmonary abnormalities [28] . Intrapulmonary shunting due to vasodilatation is found in more than 50% of cirrhotic patients evaluated for OLT. In addition, 15-30% of cirrhotic patients evaluated for OLT have underlying HPS [29, 30] . Although HPS is most commonly seen in patients with both cirrhosis and portal hypertension, it has been described in patients without portal hypertension (acute and chronic hepatitis [31] [32] [33] ), and also in those with portal hypertension without cirrhosis (nodular regenerative hyperplasia, congenital hepatic fibrosis, hepatic venous outflow obstruction and prehepatic portal hypertension [34] [35] [36] ). These studies show that advanced and long-standing liver disease is not essential for HPS to develop. In addition, a recent prospective multicenter study did not find an association between HPS and severity of liver disease in cirrhotic patients evaluated for OLT [37] .
Diagnosis
The diagnosis of HPS is established by the presence of abnormal arterial gas exchange in association with intrapulmonary vasodilation. Abnormal pulmonary gas exchange is detected by arterial blood gas (ABG) analysis showing an abnormal age-corrected alveolar-arterial oxygen gradient (>15 mmHg) with or without hypoxemia ( p a O 2 < 70 mmHg). ABGs are standardized to the sitting position; vascular shunts are more prevalent in the lung bases, so the upright position accentuates the ventilation perfusion abnormality. HPS may be missed in recumbent (e.g. hospitalized) patients. Pulse oximetry is a noninvasive method that indirectly measures oxygen saturation (S p O 2 ), and is a useful screening test for HPS [38] . In addition, changes in periodic S p O 2 measurements can guide subsequent use of ABG and contrast echocardiography [39] .
Contrast echocardiography is the most sensitive screening modality to detect intrapulmonary vasodilatation. Contrast echocardiography is done by injecting agitated saline intravenously during normal transthoracic echocardiography. The injected microbubbles (contrast) appear in the right ventricle within seconds, and are normally absorbed in the lungs. Intracardiac shunting is detected by early (within three heart beats) appearance of contrast in the left ventricle. The appearance of contrast in the left ventricle after three or more beats indicates intrapulmonary shunting.
Radionuclide lung perfusion scanning with technetiumlabeled macroaggregated albumin particles can be used to quantify intrapulmonary shunting. It is less sensitive than contrast echocardiography, but may be useful in determining shunt size in patients with concomitant intrinsic pulmonary disease to determine if HPS is contributing to hypoxemia [40] . Pulmonary angiography and high-resolution chest computed tomography scan are other methods to detect intrapulmonary vasodilatation that are more invasive and less sensitive than contrast echocardiography [41] .
Pathogenesis
The most important alteration in the pathogenesis of HPS is dilatation of the precapillary and postcapillary pulmonary vasculature resulting in impaired oxygenation of venous blood as it passes through the lung [42] . Increased intrapulmonary nitric oxide has been found in human studies of HPS suggesting that nitric oxide has a role in the intrapulmonary vasodilation seen in HPS. Other studies have demonstrated increased levels of exhaled nitric oxide in cirrhotic patients with HPS that normalize after OLT and resolution of HPS. However, inhibition of nitric oxide production or action has not been shown to reliably improve HPS, and increased nitric oxide production is not unique to HPS [43] [44] [45] .
Animal models of HPS have also demonstrated increased pulmonary nitric oxide production. This may be a key event in the development of HPS through increased pulmonary vascular expression and activity of endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) [46] . Increased eNOS activity appears to result from enhanced hepatic production and release of endothelin-1 and shear stress mediated increase in pulmonary endothelial ET-B expression [47] . Therefore, endothelin-1 release appears to enhance activation of eNOS through the ET-B receptor. On the contrary, iNOS production increases as a result of intravascular macrophage accumulation, which is likely related to increased bacterial translocation. Macrophages also produce heme oxygenase-1 leading to increased carbon monoxide (CO) production, which also enhances vasodilatation [48, 49] .
In addition, angiogenesis has recently been recognized as an important contributor in the development of HPS in animal models and pertains to the activation of angiogenic pathways (vascular endothelial growth factor A) in part by intravascular monocytes [50] . Figure 2 outlines the pathophysiology of HPS.
Clinical features
Patients with HPS are often asymptomatic, so a high index of suspicion is required to establish the diagnosis. The most frequent symptom, when present, is gradually progressive dyspnea [51] . Platypnea (dyspnea on standing) and orthodeoxia (hypoxemia worsened in the upright position) are characteristic signs in HPS. Both are attributed to the predominance of vasodilatation in the lower lung fields. The upright position increases 'shunting' through these regions, and increases the ventilation-perfusion mismatch [52] . Digital clubbing and cyanosis are also frequent in HPS patients [30] . Chest radiographs are mostly normal but may show nonspecific interstitial changes. Pulmonary function tests typically demonstrate a reduced CO diffusion capacity (DLCO) in the presence of normal spirometry and lung volumes [53] . Decreased DLCO is not specific to HPS and is frequently seen in cirrhotic patients without HPS [54] .
Natural history
Although the natural history of HPS is not well characterized, current data indicate that most patients with HPS develop progressively worsening gas exchange over time and suggest that spontaneous improvement is rare [55] . Patients with HPS have a significantly lower quality of life and higher mortality when compared with cirrhotic patients without HPS [37] . OLT successfully reverses HPS, and patients with severe HPS are eligible for MELD exception points to increase priority for transplant.
Management
There are no effective medical therapies for HPS and no large, randomized trials have been done. Case reports and small studies have proposed a therapeutic role for several drugs such as aspirin [56] , norfloxacin [43, 57] , inhaled L-nitro-arginine methyl ester [43] and garlic [58] . The use of pentoxifylline has shown conflicting results in different studies [59] . Portal decompression with transjugular intrahepatic portosystemic shunt (TIPS) has been reported in some cases but without convincing evidence for improvement [60] .
Supplemental oxygen therapy is appropriate in HPS patients with hypoxemia, although no studies have evaluated survival benefit. At present OLT is the only definitive therapy for HPS with significant postoperative improvement in gas exchange or resolution in over 85% of patients. The length of time for resolution after OLT is variable and may be more than 1 year in some cases. As HPS severity increases, posttransplant mortality also increases [59] . Patients with severe HPS ( p a O 2 < 60 mmHg) are eligible for MELD exception points. Screening for HPS and consideration of OLT prior to the onset of severe hypoxemia is appropriate.
Noncirrhotic portopulmonary hypertension and hepatopulmonary syndrome
Infection with Schistosoma mansoni may be the most common form of POPH in the world. An estimated 200 million people are infected, and up to 10% may develop severe disease [61] . The parasite enters through the skin and produces an immune complex-mediated hypersensitivity reaction in the lung. S. mansoni is also associated with presinusoidal portal hypertension. When this occurs, ova bypass the liver and reenter the lungs where they set up a granulomatous inflammatory response. Pulmonary vascular remodeling may therefore occur for two reasons: the direct effect of the parasite and POPH related to portal hypertension [62] [63] [64] . Mild HPS has also been described [65] .
Coexistent portopulmonary hypertension and hepatopulmonary syndrome
A recent paper suggests the coexistence of POPH and HPS [66] . Although this seems like a contradiction, the authors report on a patient with elevated right heart pressure associated with a positive contrastenhanced echocardiogram and review other cases in the literature.
Conclusion
Portal hypertension may be associated with two pulmonary conditions: pulmonary hypertension (POPH) and intrapulmonary shunting (HPS). The pathophysiology of both conditions remains unclear. Both POPH and HPS increase the risk of death beyond the MELD score, and both improve after liver transplantation. POPH is becoming easier to treat with the availability of multiple vasodilators, but careful management during the perioperative period is required. HPS is an indication for OLT, but severe hypoxemia increases the risk of operative death.
